These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25453754)

  • 21. RSK-mediated down-regulation of PDCD4 is required for proliferation, survival, and migration in a model of triple-negative breast cancer.
    Cuesta R; Holz MK
    Oncotarget; 2016 May; 7(19):27567-83. PubMed ID: 27028868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autophagy promotes triple negative breast cancer metastasis via YAP nuclear localization.
    Chen W; Bai Y; Patel C; Geng F
    Biochem Biophys Res Commun; 2019 Dec; 520(2):263-268. PubMed ID: 31590917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
    Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
    BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression.
    Parvani JG; Davuluri G; Wendt MK; Espinosa C; Tian M; Danielpour D; Sossey-Alaoui K; Schiemann WP
    Neoplasia; 2015 Mar; 17(3):317-28. PubMed ID: 25810016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
    Guo GC; Wang JX; Han ML; Zhang LP; Li L
    Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB.
    Okita Y; Kimura M; Xie R; Chen C; Shen LT; Kojima Y; Suzuki H; Muratani M; Saitoh M; Semba K; Heldin CH; Kato M
    Sci Signal; 2017 Apr; 10(474):. PubMed ID: 28400538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.
    Wang ZT; Chen ZJ; Jiang GM; Wu YM; Liu T; Yi YM; Zeng J; Du J; Wang HS
    Cell Signal; 2016 May; 28(5):506-515. PubMed ID: 26876786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer.
    Zhao C; Qiao Y; Jonsson P; Wang J; Xu L; Rouhi P; Sinha I; Cao Y; Williams C; Dahlman-Wright K
    Cancer Res; 2014 Jul; 74(14):3983-94. PubMed ID: 24830720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
    Maire V; Némati F; Richardson M; Vincent-Salomon A; Tesson B; Rigaill G; Gravier E; Marty-Prouvost B; De Koning L; Lang G; Gentien D; Dumont A; Barillot E; Marangoni E; Decaudin D; Roman-Roman S; Pierré A; Cruzalegui F; Depil S; Tucker GC; Dubois T
    Cancer Res; 2013 Jan; 73(2):813-23. PubMed ID: 23144294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIC1 silencing in triple-negative breast cancer drives progression through misregulation of LCN2.
    Cheng G; Sun X; Wang J; Xiao G; Wang X; Fan X; Zu L; Hao M; Qu Q; Mao Y; Xue Y; Wang J
    Cancer Res; 2014 Feb; 74(3):862-72. PubMed ID: 24295734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polo-Like Kinase 1(PLK1) Immunohistochemical Expression in Triple Negative Breast Carcinoma: A Probable Therapeutic Target.
    Salama ME; Khairy DA
    Asian Pac J Cancer Prev; 2021 Dec; 22(12):3921-3925. PubMed ID: 34967572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LIPG signaling promotes tumor initiation and metastasis of human basal-like triple-negative breast cancer.
    Lo PK; Yao Y; Lee JS; Zhang Y; Huang W; Kane MA; Zhou Q
    Elife; 2018 Jan; 7():. PubMed ID: 29350614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SMC1 promotes epithelial-mesenchymal transition in triple-negative breast cancer through upregulating Brachyury.
    Li K; Ying M; Feng D; Chen Y; Wang J; Wang Y
    Oncol Rep; 2016 Apr; 35(4):2405-12. PubMed ID: 26781859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
    Shapira I; Lee A; Vora R; Budman DR
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis.
    Cerqueira OL; Truesdell P; Baldassarre T; Vilella-Arias SA; Watt K; Meens J; Chander H; Osório CA; Soares FA; Reis EM; Craig AW
    Oncotarget; 2015 Apr; 6(11):9397-408. PubMed ID: 25823823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progression.
    He J; McLaughlin RP; van der Beek L; Canisius S; Wessels L; Smid M; Martens JWM; Foekens JA; Zhang Y; van de Water B
    Oncogene; 2020 May; 39(20):4118-4131. PubMed ID: 32235890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
    D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK
    Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor.
    Takada M; Zhuang M; Inuzuka H; Zhang J; Zurlo G; Zhang J; Zhang Q
    Oncotarget; 2017 Jan; 8(4):6787-6795. PubMed ID: 28036276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.